@article{5a027323e0654993837226ca356143ee,
title = "Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma",
abstract = "Introduction: Majority of patients with Hodgkin lymphoma (HL) can be successfully cured with frontline conventional therapeutics. Approximately 50–60% of those whose disease recur or is refractory to conventional treatment, can be cured with salvage therapies followed by autologous hematopoietic cell transplantation (AHCT). Conventional treatments, however, may cause significant long-term toxicities. Areas covered: This article reviews the treatment advances in HL with the incorporation of novel and targeted agents that are aimed to improve cure rates while reducing toxicities. Expert opinion: Brentuximab vedotin (BV) and checkpoint inhibitors have demonstrated clear clinical benefit in HL. Majority of patients receive BV before or directly after AHCT as part of salvage or maintenance regimens. In patients who relapse after AHCT, checkpoint inhibitors are the treatment of choice, either as a stand-alone therapy or more commonly as a bridge to a potentially curative allogeneic hematopoietic cell transplantation (alloHCT). A multitude of other targeted agents and combinations, as well as cellular and immunotherapeutic in HL, are under investigation.",
keywords = "Autologous transplant, CAR T cell, CD30 directed antibody, Hodgkin lymphoma, allogeneic transplant, checkpoint blockade, immunotherapy, novel agents, transplant",
author = "Dahi, {Parastoo B.} and Moskowitz, {Craig H.} and Giralt, {Sergio A.} and Lazarus, {Hillard M.}",
note = "Funding Information: CH Moskowitz has been on the scientific advisory board for Astra Zeneca, Karyopharm, Merck, Seattle Genetics, Takeda and Vaniam group; and has received research funding from: BMS, Merck, and Seattle Genetics. SA Giralt is on the advisory board for Amgen, Actinum, Celgene, Johnson & Johnson, Jazz Pharmaceutical, Takeda, Novartis, Kite, Spectrum Pharma; and has received research funding from: Amgen, Actinum, Celgene, Johnson & Johnson, Miltenyi and Takeda. HM Lazarus has been a consultant and promotional speaker for Seattle Genetics and AstraZeneca. He is a promotional speaker for Pharmacyclics and is on the Data Safety Monitoring Board of Celgene. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript apart from those disclosed. Funding Information: This research is supported in part by grants from the National Institute of Health, National Cancer Institute (P01 CA23766 and P30 CA008748). Funding Information: A peer reviewer on this manuscript was an author on the ECHELON-1 study and has had research financed by Takeda and BMS. Another reviewer on this manuscript has received research funding from Seattle Genetics, BMS, Merck, Celgene, Pharmacyclics and has consulted for Seattle Genetics, BMS, Kite, Kyowa, Astra-Zeneca. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.",
year = "2019",
month = apr,
day = "3",
doi = "10.1080/17474086.2019.1593135",
language = "English (US)",
volume = "12",
pages = "255--264",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "4",
}